A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care
When the early signs of illness appeared during the patient's first months of life, KFSHRC teams raced against time to stabilize her condition. She was diagnosed with a congenital deficiency in plasminogen, a protein essential for dissolving blood clots, resulting in fibrous deposits that posed serious threats to her tissues and organs.
The complexity of her case posed both medical and quality-of-life challenges, requiring a comprehensive, multidisciplinary care system. This extended beyond medical treatment to include all facets of life-supporting care. Teams from nursing, nutrition, and information technology joined hematology and transplant specialists to ensure the young girl's well-being.
In a reflection on the early days, the patient's father said: 'My daughter suffered from the moment she was born. She cried constantly and couldn't nurse. We lived in continuous worry with no clear answers until God opened a door of hope. Today, thanks to God first, and then to the remarkable healthcare capabilities provided by the Government of the Custodian of the Two Holy Mosques and His Royal Highness the Crown Prince, may God preserve them, we witness our daughter's recovery from this rare disease after two decades of struggle.'
Throughout the years of treatment, the patient relied on regular intravenous doses of plasminogen, along with eye drops to reduce the disease's effect on her vision. The annual cost of treatment exceeded 6 million SAR, fully covered by the Saudi government. This reflects the Kingdom's profound commitment to human health and its investment in quality of life even in the most complex medical cases.
Dr. Hazzaa Al-Zahrani, Director of Adult Hematology and Stem Cell Transplant Division at KFSHRC Riyadh and the supervising physician, explained that managing the case required a precise and long-term approach to prevent complications and ensure stability. The decision to proceed with a liver transplant came after careful consideration as an extraordinary therapeutic option for an exceptionally rare case. The success of the procedure marked a turning point in her medical journey and a beacon of hope for patients facing similar conditions worldwide.
This approach is deeply rooted in the vision of King Faisal Specialist Hospital & Research Centre, which places the patient at the core of every practice and is committed to delivering integrated care where scientific expertise meets human compassion, in line with its mission to serve society at the highest standards.
For more information, visit www.kfshrc.edu.sa or contact our media team at [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
2 days ago
- Gulf Today
Saudi ‘Sleeping Prince' Al Waleed passes away after 20 years in coma
A wave of sorrow swept across social media following the official announcement of the death of 'The Sleeping Prince', Prince Al-Waleed bin Khalid bin Talal Al Saud, at the age of 36. He had spent 20 of those years in a coma after a tragic car accident in 2005, which left him unconscious ever since. Prince Khalid Bin Talal mourned his son on his account on X (formerly Twitter), writing: 'O tranquil soul, return to your Lord, well-pleased and pleasing [to Him]. Enter among My [righteous] servants and enter My Paradise.' He added: 'With hearts that believe in God's will and decree, and with deep sadness and sorrow, we mourn our beloved son, Prince Al-Waleed Bin Khalid Bin Talal Bin Abdulaziz Al Saud, may God have mercy on him, who passed away today.' Prince Khalid announced that the funeral prayer will be held on Sunday, with mourning gatherings to continue for three days: Sunday, Monday, and Tuesday. After the news of the prince's death broke, social media was filled with condolences. Users shared prayers and messages of sympathy with the family, asking God to have mercy on the late prince. Over the years, the emotional story of 'The Sleeping Prince' continued to captivate the public, especially amid repeated rumors about his possible death or signs of waking. The late prince suffered a devastating car accident in 2005 while he was studying at a military college. The incident left him in a coma and earned him the nickname 'The Sleeping Prince.' Despite numerous intensive medical efforts, including visits from international doctors – a team of American specialists and a Spanish neurologist – no significant improvement in his condition was ever achieved. His family never lost hope, with his father often sharing images by his son's bedside to reassure loved ones and supporters of his son's condition. There were moments that renewed hope. In 2019, Princess Rima bint Talal posted a video showing the prince moving his head from right to left, writing: 'The Almighty, the Merciful... Al-Waleed bin Khalid is moving his head from side to side. Praise and thanks be to You, O Lord.' In April this year, Prince Al-Waleed's name trended again across social platforms after Princess Rima posted another photo of him, reigniting the story of faith, patience, and endurance. Princess Rima bint Talal, sister of Prince Khalid, shared a touching message on her official account: 'My beloved Al-Waleed bin Khalid, twenty-one years and you are always present in our hearts and in the prayers of your loved ones. O Allah, heal Your servant Al-Waleed – only You know his weakness, O Lord of the heavens and the earth.' Just months ago, Prince Khalid announced medical developments after doctors noticed swelling in the prince's glands on both sides, prompting further tests. In 2020, after 15 years in a coma, Al-Waleed moved his hand — a moment that once again sparked hope among family and supporters. Since falling into a coma in 2005, Prince Al-Waleed bin Khalid bin Talal became a symbol of patience and deep faith in the Kingdom of Saudi Arabia. Two decades passed, yet his story remained alive in the hearts of the Saudi people — a lasting symbol of hope and resilience.
Zawya
2 days ago
- Zawya
IVD Medical Holding Limited (01931.HK): Officially launched the application for the US stablecoin license and accelerated the landing of the IVDNewCo Exchange ecosystem
HONG KONG SAR - Media OutReach Newswire - 21 July 2025 – IVD Medical Holding Limited( - Forward-looking layout of the historical opportunity of the US "Genius Act", the IVDD stablecoin plan is gathering momentum to set sail and build a new global infrastructure for medical innovative drugs RWA! In the wave of deep integration of global digital finance and medical innovation, IVD Medical Holding Limited( took the lead in building the "NewCo+RWA" Web3 exchange ecosystem (IVDNewCo Exchange) with the construction of medical innovative drugs high-tech assets as the core and the supporting stablecoin "IVDDollar" (IVDD) plan as the core strategy, leading the digital revolution of global medical innovation assets. On July 20, 2025, the Board of Directors is pleased to announce that the US subsidiary carrying the Group's aforementioned core strategic mission has landed, and the IVDNewCo Exchange ecosystem has officially landed on the international financial stage. The company released the latest announcement today, officially announcing two milestones: the US wholly-owned subsidiary IVD GROUP INC. has completed registration, and the Group has officially started the process of submitting a stablecoin license application to the US regulator through the subsidiary; at the same time, the Web3 exchange ecosystem with medical innovative drug NewCo assets as the core - IVDNewCo Exchange and its supporting stablecoin IVDD have entered a substantive stage. This strategic move not only marks the Group's leading position in the field of compliant digital finance for medical innovative drugs, but also heralds a revolutionary breakthrough in the global medical asset liquidity and value conversion model. 1. Strategic opportunities under global regulatory resonance On July 18, 2025, local time, US President Trump signed the "Guidance and Establishment of the United States Stablecoin National Innovation Act" (hereinafter referred to as the "Genius Act") at the White House, establishing the legal status of stablecoins as "digital dollars". The implementation of this bill, together with the Stablecoin Ordinance of the Hong Kong Special Administrative Region, which will take effect on August 1, forms a regulatory synergy between the East and the West, and jointly builds the compliance cornerstone of the global stablecoin market. The report of the China Banking Research Institute pointed out that currently 99% of the world's stablecoins are anchored to US dollar assets, and US Treasury bonds have become the core choice of stablecoin reserve assets due to their low risk and high liquidity. In this context, the Group proactively laid out the application for the US stablecoin license, and on July 20 officially announced that the US subsidiary had initiated the process of submitting application materials to regulatory agencies such as the US SEC and CFTC, becoming one of the very few listed companies in the Hong Kong stock market that has completed the "Hong Kong + US" dual hub compliance architecture layout. The strategic layout of the Group is deeply in line with the global regulatory trend. By establishing the US subsidiary IVD GROUP INC., we not only meet the strict requirements of the "Genius Act" for 100% reserve asset coverage and independent auditing of stablecoin issuers, but also rely on the sandbox mechanism of the Hong Kong "Stablecoin Ordinance" to build a cross-regional regulatory endorsement system. This dual hub model provides the IVDNewCo Exchange ecosystem with globally rare compliant liquidity support, enabling the Group to establish a first-mover advantage in the "Hong Kong Stock Stablecoin Concept Sector". 2. Technological Innovation: "NewCo+RWA+Stablecoin" Reconstructs the Value Chain of Medical Innovative Drug Assets The core breakthrough of the IVDNewCo Exchange ecosystem lies in the deep integration of Web3 technology and medical innovative drug assets. Relying on the commercial network covering 1,674 tertiary hospitals in China and the ability to acquire high-quality NewCo assets around the world, the Group has created the world's first RWA (real world asset) tokenization platform focusing on medical innovative drugs. The platform achieves the following innovations through blockchain technology: 1). Asset tokenization: converting innovative drug assets such as ADC drugs, bi-antibody therapy, and cell gene therapy in the clinical stage into tradable and divisible digital certificates to break through the liquidity bottleneck of traditional medical assets; 2). Compliance financial infrastructure: establish an underlying architecture to support the issuance, trading and settlement of IVDD stablecoins, ensuring that each $1 stablecoin corresponds to ultra-short-term U.S. Treasury bonds and other low-risk assets, meeting the U.S. SEC's "1:1 redeemable" requirements; 3). Coin-stock linkage mechanism: coordinate with Nasdaq's dual primary listing plan to explore the compound value creation model of "digital assets + traditional equity" to attract two-way inflows of traditional medical capital and crypto-native funds. The implementation of this technical architecture has been strongly supported by industry data. Public information shows that the current global innovative drug market has exceeded US$1.2 trillion, and China accounts for 6% of the market with a scale of RMB 450 billion, with an annual compound growth rate of 20.3%. Through the RWA platform, the Group expects to significantly improve the financing efficiency of innovative drug assets, while lowering the entry threshold for investors, allowing small and medium-sized investors around the world to participate in the medical innovation field that was originally limited to institutional investment. 3. Ecological synergy: creating a new paradigm for medical finance The Group's strategic advancement has always followed the three-dimensional path of "regulatory compliance-technological innovation-ecological synergy". In the United States, IVD GROUP INC.'s license application strictly follows the requirements of the Genius Act for reserve asset transparency, anti-money laundering (AML) and network security. Its technical system has passed a third-party security audit to ensure that smart contracts are free of loopholes; in Hong Kong, the Group will actively promote participation in the HKMA's stablecoin sandbox program to test reserve asset management and cross-border payment scenarios, laying the foundation for license application. More importantly, the implementation of the IVDNewCo Exchange ecosystem is reshaping the value chain of innovative medical drugs. Under the traditional model, the research and development of innovative drugs requires a cycle of up to 10 years, and 80% of the funds are concentrated in the clinical stage. Through the RWA platform, the Group can monetize clinical-stage assets in advance, provide pharmaceutical companies with low-cost financing channels, and provide investors with dynamic returns linked to the progress of drug development. For example, an ADC drug in Phase II clinical trials can attract global capital participation through tokenization, and its development progress data will be uploaded to the chain in real time to ensure that investors' rights and interests are transparent and traceable. 4. Industry Impact and Future Outlook The Group's strategic initiatives have attracted widespread attention from the capital market and the industry. After the announcement on the 17th, IVD Medical's share price opened sharply higher on the 18th, closing at HK$2.95, up 20.41% throughout the day, with a turnover exceeding HK$9.4886 million and a market value of HK$4.783 billion. Behind the market data is investors' strong confidence in the cross-border integration of "NewCo+RWA+stablecoin". Looking ahead, the Group will continue to deepen the three strategic directions of compliance expansion, technology deepening and ecological integration. Against the backdrop of the global low interest rate environment and the surge in demand for medical innovation, it will use Web3 technology as a bridge to connect traditional medical capital and digital financial innovation. We firmly believe that through compliance layout and technological innovation, the IVDNewCo Exchange ecosystem will become a value amplifier for global innovative medical drug assets, creating a win-win situation for patients, pharmaceutical companies and investors. Hashtag: #IVDMedicalHoldingLimited The issuer is solely responsible for the content of this announcement. IVD Medical Holding Limited
Zawya
6 days ago
- Zawya
KFSHRC performs world's first robotic-assisted BiVAD Implantation
A minimally invasive robotic surgery offers a life-saving option for high-risk patients who cannot undergo transplants or traditional open-heart procedures King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world's first implantation of two artificial pumps for biventricular support (BiVAD-HMIII) using robotic technology on a patient with advanced heart failure. This groundbreaking procedure opens new horizons in circulatory support techniques for patients with complex cardiac conditions and marks a medical achievement that culminated in the patient's recovery within a short period following the surgery. The procedure represents a major advancement in the treatment of bilateral heart failure, which was traditionally performed through full sternotomy, an approach associated with higher surgical risks and prolonged recovery. However, the cardiac surgery team at KFSHRC, led by Prof. Feras Khaliel, successfully performed the operation through small incisions using remotely controlled high-precision robotic arms, resulting in reduced blood loss, lower risk of infection, and faster patient recovery. The 61-year-old patient was admitted after spending over two months bedridden, suffering from end-stage heart failure unresponsive to medical therapy, in addition to multiple chronic conditions including diabetes, stroke, and renal impairment. After a comprehensive clinical evaluation, the patient was deemed ineligible for a heart transplant, making robotic implantation of the artificial pumps a vital and unique solution suited to his health status. This milestone reflects the integration of expertise across multiple departments at KFSHRC including cardiac surgery, cardiology, anesthesia, critical care, biomedical engineering, and advanced life support. The procedure was meticulously planned and benefited from 3D imaging technologies, real-time surgical navigation, and innovative solutions for safely securing the mechanical assist devices. KFSHRC aims to publish the results of this procedure in peer-reviewed medical journals and present them at global cardiology conferences to promote knowledge exchange and establish innovative partnerships with leading international centers in robotic care and advanced heart failure management. This achievement adds to KFSHRC's track record in robotic surgery which includes the world's first fully robotic heart transplant and the World's First Robotic-Assisted Artificial Heart Pump Implantation. These milestones serve as evidence of its leadership in adopting cutting-edge cardiac technologies and managing critical conditions with the highest standards of precision and safety, further reinforcing its position as a leading academic medical center both regionally and globally. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 20th globally in the list of the world's top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world's best 250 hospitals and included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
